首页> 美国卫生研究院文献>BMJ Open Access >Original article: Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial

【2h】

Original article: Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial

机译：原始文章：雷珠单抗治疗引起视力障碍的糖尿病性黄斑水肿（DME）的成本效益：RESTORE试验的证据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background/aimsTo evaluate the cost-effectiveness of ranibizumab as either monotherapy or combined with laser therapy, compared with laser monotherapy, in the treatment of diabetic macular oedema (DME) causing visual impairment from a UK healthcare payer perspective.

机译：背景/目的从英国医疗付款人的角度评估雷珠单抗单药治疗或激光治疗与激光单药治疗相结合的成本效益，以治疗引起视力障碍的糖尿病性黄斑水肿（DME）。

著录项

期刊名称 BMJ Open Access
作者
Paul Mitchell; Lieven Annemans; Meghan Gallagher; Rafiq Hasan; Simu Thomas; Kerry Gairy; Martin Knudsen; Henrietta Onwordi;
展开▼
作者单位

展开▼
年(卷),期 -1(96),5
年度 -1
页码 688–693
总页数 6
原文格式 PDF
正文语种
中图分类
关键词
Ranibizumab diabetic macular oedema visual impairment cost-effectiveness macula treatment medical clinical trial epidemiology public health vision retina;

机译：雷尼单抗;糖尿病性黄斑水肿;视力障碍;成本效益;黄斑;治疗医学;临床试验;流行病学;公共卫生;视力;视网膜;

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: Evidence from the RESTORE trial [J] . MitchellP., AnnemansL., GallagherM., British journal of ophthalmology . 2012,第5期

机译：雷珠单抗治疗引起视力障碍的糖尿病性黄斑水肿（DME）的成本效益：RESTORE试验的证据
2. Ranibizumab for the treatment of visual impairment due to diabetic macular edema: evidence from recent clinical trials [J] . Laura Distefano, Anna Boixadera Espax, Charlotte Wolley-Dod, Clinical investigation . 2012,第4期

机译：雷尼单抗治疗糖尿病性黄斑水肿引起的视力障碍：最近临床试验的证据
3. Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to diabetic macular edema: 12-month results from the 36-month BOREAL-DME study [J] . Garcher Catherine P. Creuzot, Massin Pascale, Kodjikian Laurent, Investigative ophthalmology & visual science . 2017,第8期

机译：Ranibizumab的现实世界成果0.5毫克治疗法国患者视力障碍因糖尿病黄斑水肿：36个月的Boreal-DME学习的12个月的结果
4. Inertial sensor based gait analysis discriminates subjects with and without visual impairment caused by simulated macular degeneration [C] . Christoph M. Kanzler, Jens Barth, Jochen Klucken, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：基于惯性传感器的步态分析可区分是否患有由模拟黄斑变性引起的视力障碍
5. Prediction of visual acuity loss and indications for laser treatment in patients with diabetic macular edema using the Heidelberg Retina Tomograph. [D] . O'Neal, Dennis A. 2007

机译：使用海德堡视网膜断层扫描仪预测糖尿病性黄斑水肿患者的视力下降和激光治疗的适应症。
6. Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective [O] . Stephane A Régnier, William Malcolm, Jennifer Haig, 2015

机译：雷尼单抗与阿柏西普治疗糖尿病性黄斑水肿所致视力障碍的成本效益：英国医疗保健观点
7. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial [O] . Mitchell, Paul, Annemans, Lieven, Gallagher, Meghan, 2012

机译：雷珠单抗治疗引起视力障碍的糖尿病性黄斑水肿（DME）的成本效益：RESTORE试验的证据

Original article: Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial

摘要

著录项

相似文献

相关主题

期刊订阅